[go: up one dir, main page]

IN2014DN05865A - - Google Patents

Info

Publication number
IN2014DN05865A
IN2014DN05865A IN5865DEN2014A IN2014DN05865A IN 2014DN05865 A IN2014DN05865 A IN 2014DN05865A IN 5865DEN2014 A IN5865DEN2014 A IN 5865DEN2014A IN 2014DN05865 A IN2014DN05865 A IN 2014DN05865A
Authority
IN
India
Prior art keywords
infection
mycobacterium
antigens
prevention
treatment
Prior art date
Application number
Inventor
James Anthony Triccas
NADANACHANDRAN Rachel PINTO
Warwick John Britton
Original Assignee
Univ Sydney
Centenary Inst Of Cancer Medic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sydney, Centenary Inst Of Cancer Medic filed Critical Univ Sydney
Publication of IN2014DN05865A publication Critical patent/IN2014DN05865A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07004—Sulfate adenylyltransferase (2.7.7.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Mycobacterium tuberculosisThe invention relates to the identification of antigens including Mycobacterium sulphate assimilation pathway components such as CysD for preventing and treating Mycobacterium infection especially but not exclusively infection; to expression systems including live Mycobacterium for expression of said antigens for prevention and treatment of said infection; and to use of said antigens and expression systems for prevention and treatment of said infection.
IN5865DEN2014 2011-12-22 2012-12-20 IN2014DN05865A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579166P 2011-12-22 2011-12-22
PCT/AU2012/001569 WO2013091004A1 (en) 2011-12-22 2012-12-20 Prevention and treatment of mycobacterium infection

Publications (1)

Publication Number Publication Date
IN2014DN05865A true IN2014DN05865A (en) 2015-05-22

Family

ID=48667508

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5865DEN2014 IN2014DN05865A (en) 2011-12-22 2012-12-20

Country Status (7)

Country Link
US (2) US9610337B2 (en)
EP (1) EP2794885B1 (en)
CN (1) CN104271744B (en)
AU (1) AU2012357637B9 (en)
ES (1) ES2655190T3 (en)
IN (1) IN2014DN05865A (en)
WO (1) WO2013091004A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105567660B (en) * 2016-01-08 2018-11-20 中国人民解放军第四军医大学 A kind of method and its application of Recombinant protein expression mycobacterium tuberculosis Rv2837c activated protein
EP3743103A4 (en) * 2018-01-26 2021-03-17 The Regents of The University of California Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis
JP2021522245A (en) * 2018-04-26 2021-08-30 チルドレンズ ナショナル メディカル センターＣｈｉｌｄｒｅｎ’Ｓ Ｎａｔｉｏｎａｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Mycobacterial antigen composition and usage
EP3797791A1 (en) * 2019-09-26 2021-03-31 Universidad De Zaragoza Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria
WO2021243417A1 (en) * 2020-06-05 2021-12-09 Centenary Institute Of Cancer Medicine And Cell Biology Immunogenic formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828510A1 (en) * 1995-05-23 1998-03-18 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
WO2002004018A2 (en) * 2000-07-10 2002-01-17 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
US6858213B2 (en) 2001-04-20 2005-02-22 The Regents Of The University Of California Mycobacterial sulfation pathway proteins and methods of use thereof
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
EP2355798A1 (en) * 2008-11-12 2011-08-17 Statens Serum Institut Modified cationic liposome adjuvans

Also Published As

Publication number Publication date
US9610337B2 (en) 2017-04-04
WO2013091004A1 (en) 2013-06-27
CN104271744A (en) 2015-01-07
AU2012357637A1 (en) 2014-07-17
US20160022795A1 (en) 2016-01-28
CN104271744B (en) 2017-06-06
ES2655190T3 (en) 2018-02-19
EP2794885B1 (en) 2017-10-04
US9931391B2 (en) 2018-04-03
EP2794885A4 (en) 2015-07-22
EP2794885A1 (en) 2014-10-29
AU2012357637B9 (en) 2017-10-19
AU2012357637B2 (en) 2017-09-21
US20170173137A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
MY192848A (en) Compositions and methods for the treatment of hemoglobinopathies
IN2015DN02634A (en)
IN2014CN03555A (en)
NZ708928A (en) Mannose derivatives for treating bacterial infections
MX359327B (en) Methods and compositions for treating huntington's disease.
WO2015003816A3 (en) Cystobactamides
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
PH12013502135A1 (en) Antimicrobial compounds and methods of making and using the same
MX349886B (en) Anti-pseudomonas psl binding molecules and uses thereof.
IN2012DN00624A (en)
GB201103062D0 (en) Method
IN2015DN00438A (en)
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2021011946A (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency.
MX2015015416A (en) Acc inhibitors and uses thereof.
MY195743A (en) Isoxazole Hydroxamic Acid Compounds as LPXC Inhibitors
SG10201807059QA (en) Agents for influenza neutralization
SG10201900541QA (en) Derivatives of xanthone compounds
IN2014DN05865A (en)
MX348397B (en) Use of extracts from filipendula for the treatment and prophylaxis of chronic pain conditions.
AU2015308650A8 (en) Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof
MX2015011198A (en) Antiviral compounds.
IN2014DN00254A (en)
PH12017501872A1 (en) Methods of treating diseases
MX347541B (en) Sialic acid analogs.